Ovarian cancer is one of the most challenging gynecologic malignancies. The majority of patients tend to present late with advanced stage of disease given the lack of symptoms and no effective screening tests available. The 5-year overall survival has not obviously been improved nearly two decades. Although many patients display a good initial response to these conventional therapies

most of them experience relapse and ultimately develop platinum resistance

which makes the treatment and the choices more and more difficult. In recent years

a great deal of research has been devoted to targeted therapies. The application of poly-ADP ribose polymerase inhibitors (PARPi) is revolutionizing the treatment of epithelial ovaries. This article summarizes the current situations of PARPi-related genetic testing

maintenance treatment at initial and recurrent ovarian cancer

post-line treatment at recurrent ovarian cancer and related focal issues

in order to provide a reference for better clinical application of PARPi.